Interní Med. 2005; 7(6): 303-305

PET/CT in clinical practice

MUDr. Jana Votrubová CSc, MUDr. Otakar Bělohlávek CSc
PET centrum, Nemocnice Na Homolce, Praha

The aim of this paper is to provide information about the clinical usefulness of hybrid imaging modality positron emission tomography and computed tomography (FDG-PET/CT) in oncology. Patients with a known malignant disease and patients with a suspicion of malignancy represent the major part of our investigations. The hybrid system, combining a spiral computed tomograph (CT) and a dedicated positron emission tomography scanner (PET) provides both morphological and metabolic information at one investigation. This helps to increase the sensitivity and specificity of both imaging modalities and is very time-sparing.

Keywords: Key words: positron emission tomography PET, computed tomography CT, fluorodeoxyglucose FDG, diagnostics, oncology.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Votrubová J, Bělohlávek O. PET/CT in clinical practice. Interní Med. 2005;7(6):303-305.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bělohlávek O, Fencl P. Hybridní zobrazování výpočetní a pozitronovou emisní tomografií. Interní medicína pro praxi 2004; 6, 2: 61-63.
    2. Bělohlávek O, Slabý J, Táborská K, Trněný M, Klener P. Prognostic value of PET after second cycle of chemotherapy at malignant lymphoma. Eur J Nucl Med 2001; 28: 961. Go to original source...
    3. Bělohlávek O, Košatová K, Melínová L, Šťastný B, Skácel Z, Marel M, Schützner J, Pafko P. Metabolic characterisation of solitary pulmonary nodules by positron emission tomography with FDG - preliminary report. Nucl Med Rew 2001; 4: 97-100.
    4. Kantorová I, Lipská L, Bělohlávek O, Visokai V, Trubač M, Schneiderová M. Routine 18F-FDG PET preoperative staging of colorectal cancer: Comparison with conventional staging and its Impact on treatment decision making. J Nucl Med 2003; 44: 1784-1788. Go to PubMed...
    5. Oehr P, Biersack HJ, Coleman. R.E. PET and PET/CT in oncology. Springer Verlag Berlin 2004; 350s. Go to original source...
    6. Pacák J, Černý M. Deoxyfluorglukosa, mezník ve vývoji pozitronové emisní tomografie (historie jednoho výzkumu). Chem. Listy 2002; 96: 704-707.
    7. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference,, ,Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-1723. Go to original source... Go to PubMed...
    8. Schützner J, Pafko P, Stolz A, Bělohlávek O, Skácel Z, Košatová K. Pohled chirurga na význam pozitronové emisní tomografie - PET (se zaměřením na plicní nádorové postižení). Rozhl. Chir. 2004; 82. 11: 596-599. Go to PubMed...
    9. Votrubová J, Jarůšková M, Bělohlávek O, Fencl P. The role of FDG PET/CT in detection of local recurrence of colorectal cancer. Gut 2004; 53: suppl.VI. A60.
    10. Votrubová J, Fencl P. Hybridní zobrazování PET/CT. Čes. Radiol. 2004; 58/5: 333-337.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.